A novel leflunomide derivative, FK778, for immunosuppression after kidney transplantation in dogs

Surgery

Volumn 132, Issue 1, 2002, Pages 72-79

  Jin, Maeng Bong ^a,b   Nakayama, Masato ^a,b   Ogata, Toshiro ^a,b   Fujita, Miri ^a,b   Mino, Kazuhiro ^a,b   Taniguchi, Masahiko ^a,b   Suzuki, Tomomi ^a,b   Shimamura, Tsuyoshi ^a,b   Furukawa, Hiroyuki ^a,b   Todo, Satoru ^a,b  

^a First Department of Surgery ^*  (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; CYCLOSPORIN A; LEFLUNOMIDE; MALONONITRILAMIDE; TACROLIMUS; TERIFLUNOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CONFERENCE PAPER; CONTROLLED STUDY; DIARRHEA; DOG; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; HISTOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PYRIMIDINE METABOLISM; SURVIVAL TIME; VOMITING;

EID: 0036076671     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1067/msy.2002.125390     Document Type: Article

References (25)

1. Two activity of the immunosuppressive metabolite of leflunomide, A77 1726: Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation
2. Effect of leflunomide and other immunosuppressive agents on T cell proliferation in vitro
3. Regulation of B cell function by the immunosuppressive agent leflunomide
4. The use of leflunomide in transplantation immunology
5. Leflunomide: An immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune disease
6. Is there a place for leflunomide in the treatment of rheumatoid arthritis?
7. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: Results of a randomized, placebo-controlled, phase II study
8. Malononitrilamides synergistically prevent acute and treat ongoing skin allograft rejection with cyclosporine
9. Malononitrilamides 715 and 279 prolong rat cardiac allograft survival, reverse ongoing rejection, inhibit allospecific antibody production and interact positively with cyclosporin
10. Immunosuppression with the new leflunomide (LFM) analog, HMR1715 Plus cyclosporine (CsA) reduces clinical and histologic evidence of renal allograft rejection in MLR mismatched dogs
11. Immunosuppression of canine, monkey, and baboon allografts by FK506: With special reference to synergism with other drugs and to tolerance induction
12. FK 506 assay past and present: Characteristics of FK 506 ELISA
13. Measurement of cyclosporine concentrations in whole blood: HPLC and radioimmunoassay with a specific monoclonal antibody and 3H- or 125I-labeled ligand compared
14. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans
15. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomized, multicentre trial
16. Use of leflunomide in human renal transplantation
17. Comparative effects of malononitriloamide analogs of leflunomide on whole blood lymphocyte stimulation in humans, rhesus macaques, cats, dogs, and rats
18. Single- and multiple-dose pharmacokinetics and pharmacodynamics of leflunomide's active metabolite A77 1726 in normal Lewis rats
19. Leflunomide in experimental transplantation: Control of rejection and antibody production, reversal of acute rejection, and interaction with cyclosporine
20. Synergism of the malononitrilamides 279 and 715 with cyclosporine A in the induction of long-term cardiac allograft survival
21. Malononitrilamides and tacrolimus additively prevent acute rejection in rat cardiac allografts
22. An evaluation of leflunomide in the canine renal transplantation
23. In vivo activity of leflunomide: Pharmacokinetic analyses and mechanism of immunosuppression
24. Potentiation of immunosuppressive efficacy by combining the novel leflunomide analog, HMR 279, with microemulsion cyclosporine in a rat lung transplantation model
25. Single-and-multiple-dose pharmacokinetics and pharmacodynamics of leflunomide's active metabolite A77 1726 in normal Lewis rats